The CEO of Novo Nordisk raises concerns about compounded semaglutide’s potentially fatal side effects, citing FDA reports of ten fatalities.
Novo Nordisk highlights patient safety issues due to the unregulated and increasing popularity of compounded formulations.
Novo Nordisk CEO Lars Fruergaard Jorgensen issued a severe warning to American consumers regarding compounded forms of semaglutide, a medication that was first created under the brands Ozempic and Wegovy to treat diabetes and obesity.
Citing the FDA’s adverse event database, which shows at least 10 recorded deaths and more than 100 hospitalizations linked to compounded semaglutide, Jorgensen emphasized the serious hazards.
“People believe they’re getting real semaglutide,” Jorgensen told CNN. “However, these modified forms, which are frequently marketed as “semaglutide,” are not our product and are not protected by regulations.
” He stressed that Novo Nordisk does not distribute semaglutide for compounding and is the only producer of the FDA-approved medication.
Numerous reports of serious side effects from compounded semaglutide have been recognized by the FDA, including instances connected to dosing mistakes and fake formulations.
Numerous reports of serious side effects from compounded semaglutide have been recognized by the FDA, including instances connected to dosing mistakes and fake formulations.
Compounded medications are not as closely regulated by the FDA as approved equivalents, which raises safety issues as manufacturers and pharmacies produce these substitutes, especially during shortages.
Semaglutide is still on the FDA’s shortages list, which permits compounding, even with recent supply improvements. In an effort to find a quick solution, Novo Nordisk is collaborating closely with the FDA on supply-related concerns.
To guarantee safe treatment in the meantime, the business advises individuals to speak with their healthcare practitioners and select FDA-approved choices.
Compounded medications are not as closely regulated by the FDA as approved equivalents, which raises safety issues as manufacturers and pharmacies produce these substitutes, especially during shortages.
